Cognition Therapeutics Analyst Price Targets

Cognition Therapeutics Inc

CGTXNASDAQ

Trade with Public

$0.7500

0.02022.77%

Últ. Act.: Oct 19, 6:44 PM

$0.7500

0.02022.77%

Panorámica general Noticias Previsión de beneficios EventosPrecios objetivoFinanzas Sentimiento Propiedad Comparar Informe de acciones

Cognition Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Cognition Therapeutics (CGTX).

Price Target Range — 9 Quarters

Analyst Consensus — 6 Analysts

5Buy

1Hold

Consensus RatingBuy# Analysts6Avg. Consensus PT$6Upside to Avg. PT+666.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Mar 27, 2026	Chardan Capital	Daniil Gataulin	Maintained	Buy	$4
Dec 4, 2025	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$3
Nov 21, 2025	B. Riley Securities	William Woods	PT Raise	Buy	$2→$3
Nov 19, 2025	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$3
Aug 8, 2025	Chardan Capital	Daniil Gataulin	Maintained	Buy	$4
Jun 26, 2025	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$3
May 27, 2025	HC Wainwright & Co.	Raghuram Selvaraju	PT Cut	Buy	$5→$3
May 8, 2025	Chardan Capital	Daniil Gataulin	PT Cut	Buy	$8→$4
Mar 24, 2025	HC Wainwright & Co.	Raghuram Selvaraju	PT Cut	Buy	$6→$5
Mar 21, 2025	Chardan Capital	Daniil Gataulin	PT Cut	Buy	$11→$8
Feb 26, 2025	Chardan Capital	Daniil Gataulin	Maintained	Buy	$11
Dec 19, 2024	B. Riley Securities	Mayank Mamtani	Upgrade	Neutral→Buy	$1→$2
Dec 19, 2024	Chardan Capital	Daniil Gataulin	Maintained	Buy	$11
Dec 19, 2024	HC Wainwright & Co.	Raghuram Selvaraju	PT Raise	Buy	$5→$6
Nov 27, 2024	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$5
Nov 15, 2024	Chardan Capital	Daniil Gataulin	Maintained	Buy	$11
Nov 4, 2024	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$5
Oct 31, 2024	Chardan Capital	Daniil Gataulin	Maintained	Buy	$11
Aug 12, 2024	HC Wainwright & Co.	Raghuram Selvaraju	PT Cut	Buy	$7→$5
Aug 6, 2024	B. Riley Securities	Mayank Mamtani	Downgrade	Buy→Neutral	$5→$1

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Cognition Therapeutics, Maintains $3 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Cognition Therapeutics (NASDAQ:CGTX) with a Buy and maintains $3 price target.

Benzinga Newsdesk

PRO
B. Riley Securities Reiterates Buy on Cognition Therapeutics, Raises Price Target to $3

B. Riley Securities analyst William Woods reiterates Cognition Therapeutics (NASDAQ:CGTX) with a Buy and raises the price target from $2 to $3.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Cognition Therapeutics, Maintains $3 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Cognition Therapeutics (NASDAQ:CGTX) with a Buy and maintains $3 price target.

Benzinga Newsdesk

PRO
Chardan Capital Maintains Buy on Cognition Therapeutics, Maintains $4 Price Target

Chardan Capital analyst Daniil Gataulin maintains Cognition Therapeutics (NASDAQ:CGTX) with a Buy and maintains $4 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Cognition Therapeutics, Maintains $3 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Cognition Therapeutics (NASDAQ:CGTX) with a Buy and maintains $3 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Cognition Therapeutics, Lowers Price Target to $3

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Cognition Therapeutics (NASDAQ:CGTX) with a Buy and lowers the price target from $5 to $3.

Benzinga Newsdesk

Cognition Therapeutics Inc

Cognition Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Cognition Therapeutics, Maintains $3 Price Target

PRO
B. Riley Securities Reiterates Buy on Cognition Therapeutics, Raises Price Target to $3

PRO
HC Wainwright & Co. Reiterates Buy on Cognition Therapeutics, Maintains $3 Price Target

PRO
Chardan Capital Maintains Buy on Cognition Therapeutics, Maintains $4 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Cognition Therapeutics, Maintains $3 Price Target

PRO
HC Wainwright & Co. Maintains Buy on Cognition Therapeutics, Lowers Price Target to $3

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Cognition Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Cognition Therapeutics, Maintains $3 Price Target

PRO
B. Riley Securities Reiterates Buy on Cognition Therapeutics, Raises Price Target to $3

PRO
HC Wainwright & Co. Reiterates Buy on Cognition Therapeutics, Maintains $3 Price Target

PRO
Chardan Capital Maintains Buy on Cognition Therapeutics, Maintains $4 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Cognition Therapeutics, Maintains $3 Price Target

PRO
HC Wainwright & Co. Maintains Buy on Cognition Therapeutics, Lowers Price Target to $3

People Also Watch

People Also Watch

Cognition Therapeutics Inc

Cognition Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROHC Wainwright & Co. Reiterates Buy on Cognition Therapeutics, Maintains $3 Price Target

PROB. Riley Securities Reiterates Buy on Cognition Therapeutics, Raises Price Target to $3

PROHC Wainwright & Co. Reiterates Buy on Cognition Therapeutics, Maintains $3 Price Target

PROChardan Capital Maintains Buy on Cognition Therapeutics, Maintains $4 Price Target

PROHC Wainwright & Co. Reiterates Buy on Cognition Therapeutics, Maintains $3 Price Target

PROHC Wainwright & Co. Maintains Buy on Cognition Therapeutics, Lowers Price Target to $3

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Cognition Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROHC Wainwright & Co. Reiterates Buy on Cognition Therapeutics, Maintains $3 Price Target

PROB. Riley Securities Reiterates Buy on Cognition Therapeutics, Raises Price Target to $3

PROHC Wainwright & Co. Reiterates Buy on Cognition Therapeutics, Maintains $3 Price Target

PROChardan Capital Maintains Buy on Cognition Therapeutics, Maintains $4 Price Target

PROHC Wainwright & Co. Reiterates Buy on Cognition Therapeutics, Maintains $3 Price Target

PROHC Wainwright & Co. Maintains Buy on Cognition Therapeutics, Lowers Price Target to $3

People Also Watch

People Also Watch

PRO
HC Wainwright & Co. Reiterates Buy on Cognition Therapeutics, Maintains $3 Price Target

PRO
B. Riley Securities Reiterates Buy on Cognition Therapeutics, Raises Price Target to $3

PRO
HC Wainwright & Co. Reiterates Buy on Cognition Therapeutics, Maintains $3 Price Target

PRO
Chardan Capital Maintains Buy on Cognition Therapeutics, Maintains $4 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Cognition Therapeutics, Maintains $3 Price Target

PRO
HC Wainwright & Co. Maintains Buy on Cognition Therapeutics, Lowers Price Target to $3

PRO
HC Wainwright & Co. Reiterates Buy on Cognition Therapeutics, Maintains $3 Price Target

PRO
B. Riley Securities Reiterates Buy on Cognition Therapeutics, Raises Price Target to $3

PRO
HC Wainwright & Co. Reiterates Buy on Cognition Therapeutics, Maintains $3 Price Target

PRO
Chardan Capital Maintains Buy on Cognition Therapeutics, Maintains $4 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Cognition Therapeutics, Maintains $3 Price Target

PRO
HC Wainwright & Co. Maintains Buy on Cognition Therapeutics, Lowers Price Target to $3